3 recruiting, 2 active not recruiting, 2 completed. 7 Phase 2, 4 Phase 3, 2 Phase 1.
By phase and status
Follow EyeBiotech Ltd.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003) Tiespectus, Aflibercept - Macular Degeneration, Age-Related Macular Degeneration Phase 2 / Phase 3 Recruiting 960 2026-04-15 2026-11-17
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002) Tiespectus, Aflibercept - Macular Degeneration, Age-Related Macular Degeneration Phase 2 / Phase 3 Recruiting 960 2026-03-27 2026-11-17
A Dose-masked Study of Intravitreal Remigromig (EYE103) in Participants With NVAMD or Macular Edema Following BRVO Remigromig, Aflibercept 2.0 mg - Neovascular Age-Related Macular Degeneration (NVAMD), Branch Retinal Vein Occlusion (BRVO) Phase 2 Recruiting 160 2025-09-12 2026-10-20
A Study of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME Remigromig, Ranibizumab - Diabetic Macular Edema (DME) Phase 2 / Phase 3 Active not recruiting 1054 2025-04-16 2026-10-30
A 2-part Study Consisting of a Multiple Ascending Dose Safety Study in Participants With Macular Edema Following Branch Retinal Vein Occlusion and a Dose-finding Safety and Preliminary Efficacy Study in Participants With Either Diabetic Macular Edema or Neovascular Age-related Macular Degeneration EYE201 - Diabetic Macular Edema (DME), Neovascular Age-related Macular Degeneration (NVAMD) Phase 1 / Phase 2 Completed 38 2024-11-12 2026-08-24
A Study to Evaluate the Efficacy and Safety of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME Ranibizumab, Remigromig - Diabetic Macular Edema (DME) Phase 2 / Phase 3 Active not recruiting 984 2024-08-07 2026-11-10
A 2-part Study Consisting of Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Masked Study to Assess the Safety and Efficacy of Intravitreal (IVT) Remigromig (EYE103) in Patients With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD) Remigromig - Neovascular Age-related Macular Degeneration (NVAMD), Diabetic Macular Edema (DME) Phase 1 / Phase 2 Completed 33 2023-06-12 2026-11-03
Conditions studied Macular Degeneration (3) · Choroidal Neovascularization (2) · Retinal Vein Occlusion (2) · Wet Macular Degeneration (2)
Interventions aflibercept (3) · Ranibizumab (2)
Countries United States (7) · Puerto Rico (5) · Argentina (4) · Colombia (3) · Spain (3) · United Kingdom (3) · Australia (2) · Austria (2) · Brazil (2) · Croatia (2) · Czechia (2) · France (2) · Germany (2) · Hungary (2) · Israel (2)
Top investigators Charles Miller, MD PhD (3)
NIH funding 2025 (1)